Nanotechnology Now

Our NanoNews Digest Sponsors





Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Mersana Therapeutics, Inc. Appoints John H. van Duzer, Ph.D., as Vice President of Manufacturing and Pharmaceutical Sciences

Abstract:
Mersana, a cancer therapeutics company, announced today that John H. van Duzer, Ph.D. has joined the company as Vice President of Manufacturing & Pharmaceutical Sciences.

Mersana Therapeutics, Inc. Appoints John H. van Duzer, Ph.D., as Vice President of Manufacturing and Pharmaceutical Sciences

CAMBRIDGE, MA | Posted on January 16th, 2008

"John van Duzer adds a critical component to the Mersana management team with his manufacturing and development experience," said Julie A. Olson, Ph.D., President and CEO at Mersana. "As a clinical development-stage company, manufacturing plays a key role in the advancement of our products and John's contributions will impact our entire pipeline. We are also fortunate that John's early experience in research enables the seamless transition of candidates from research into development."

Dr. van Duzer has over eighteen years of experience in pharmaceutical R&D. As a Vice President of Manufacturing at ActivBiotics, he led efforts for the development of a liquid dosage form of a rifamycin, an oral antibacterial agent. Prior to joining ActivBiotics, Dr. van Duzer served as the Director of Chemistry at Inotek Corporation, a clinical-stage, drug development company. Prior to joining Inotek, Dr. van Duzer worked as a medicinal chemist in the research group of Ciba-Geigy and subsequently Novartis for twelve years. Most notable is his invention of lumiracoxib, a COX-2 inhibitor currently sold in a number of countries. He is a co-author of over a dozen scientific publications and is an inventor on numerous US and international patents. He received his BA in Chemistry from the University of Pennsylvania and his Ph.D. in Organic Chemistry from Yale University.

####

About Mersana Therapeutics, Inc.
Mersana, a privately held, venture backed company, utilizes its proprietary nanotechnology platform to transform existing and experimental anti-cancer agents into new, patentable drugs with superior pharmaceutical properties. The key component of Mersana's platform is Fleximer(R), a novel, biodegradable and bio-inert polymer that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer- camptothecin conjugate which is currently in Phase 1 clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.

Fleximer(R) is a trademark of Mersana Therapeutics, Inc.

For more information, please click here

Contacts:
Mersana Therapeutics, Inc.
840 Memorial Drive
Cambridge, MA 02139

Tel: 617.498.0020
Fax: 617.498.0109

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Using ultrathin sheets to discover new class of wrapped shapes: UMass Amherst materials researchers describe a new regime of wrapped shapes August 31st, 2015

New material science research may advance tech tools August 31st, 2015

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Nanomedicine

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Researchers use DNA 'clews' to shuttle CRISPR-Cas9 gene-editing tool into cells August 30th, 2015

Iranian Scientists Use Artemisia Annua Plant to Produce Breast Cancer Drugs August 29th, 2015

Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015

Announcements

Using ultrathin sheets to discover new class of wrapped shapes: UMass Amherst materials researchers describe a new regime of wrapped shapes August 31st, 2015

An engineered surface unsticks sticky water droplets August 31st, 2015

New material science research may advance tech tools August 31st, 2015

Efficiency of Nanodrug Containing Antibiotics in Treatment of Infectious Diseases Evaluated August 31st, 2015

Appointments/Promotions/New hires/Resignations/Deaths

National Space Society Welcomes Janet Ivey As New NSS Governor: Janet Ivey of Janet's Planet is NOW IN ORBIT as a member of the Board of Governors of the National Space Society August 27th, 2015

National Space Society Welcomes Geoff Notkin As New NSS Governor August 26th, 2015

Nanostart AG: First-half figures 2015 published and new supervisory board elected : Publication of first-half figures 2015 - Shareholders' meeting elected new supervisory board August 22nd, 2015

Markus Lusser is New President of Leica Microsystems August 11th, 2015

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







Car Brands
Buy website traffic